3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Recruiting
2
Sponsor Class
OTHER
3
INDUSTRY
2
NIH
1
Study Type
Interventional
2
Sponsor
Cancer Type
Gynecologic
2
Thoracic
1
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Ovarian Neoplasms
1006
Uterine Cervical Neoplasms
419
Endometrial Neoplasms
350
Breast Neoplasms
292
Carcinoma, Non-Small-Cell Lung
291
Neoplasms
238
Colorectal Neoplasms
232
Fallopian Tube Neoplasms
211
Stomach Neoplasms
192
Pancreatic Neoplasms
184
Melanoma
157
Prostatic Neoplasms
151
Triple Negative Breast Neoplasms
147
Carcinoma, Ovarian Epithelial
147
Lung Neoplasms
136
Neoplasm Metastasis
133
Squamous Cell Carcinoma of Head and Neck
130
Carcinoma, Renal Cell
130
Head and Neck Neoplasms
122
Esophageal Neoplasms
121
Urinary Bladder Neoplasms
112
Small Cell Lung Carcinoma
89
Sarcoma
80
Carcinoma, Hepatocellular
76
Recurrence
70
Carcinoma, Transitional Cell
70
Uterine Cervical Dysplasia
66
Papillomavirus Infections
66
Colonic Neoplasms
59
Cholangiocarcinoma
58
Interventions
artesunic acid
1
artenimol
1
artemisinin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
Vulvar Diseases
×
Gynecologic
×
Clear all
NCT06075264
2025-08-14
ART-VIN IIB
Frantz Viral Therapeutics, LLC
Phase 2
Recruiting
27 enrolled
NCT05592626
2025-07-09
START-001
Marengo Therapeutics, Inc.
Phase 1/2
Recruiting
365 enrolled